MiniMed Group Inc (NASDAQ:MMED) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of MiniMed Group Inc (NASDAQ:MMED) have been assigned an average rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $21.3333.

Several analysts recently commented on MMED shares. Piper Sandler reiterated a “neutral” rating and set a $16.00 price target on shares of MiniMed Group in a research report on Thursday, June 4th. Bank of America lowered their price objective on MiniMed Group from $27.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Wall Street Zen raised MiniMed Group to a “hold” rating in a research note on Saturday, March 14th. Wells Fargo & Company lowered their price objective on MiniMed Group from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, June 4th. Finally, The Goldman Sachs Group assumed coverage on MiniMed Group in a research note on Tuesday, March 31st. They set a “buy” rating and a $24.00 price objective on the stock.

MiniMed Group Price Performance

Shares of MMED opened at $15.16 on Friday. MiniMed Group has a one year low of $10.65 and a one year high of $20.48. The stock’s 50 day moving average price is $12.91.

MiniMed Group (NASDAQ:MMED) last issued its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.46). The company had revenue of $837.00 million during the quarter. The business’s revenue was up 15.6% on a year-over-year basis.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.